Rudy Li, PhD, CFA

Rudy Li, PhD, CFA is on Chardan's equity research team focusing on CNS-related companies. He has over six years of experience in biotech equity research and healthcare investment banking. Prior to joining Chardan, Rudy was an equity research analyst at Leerink Partners, covering SMID cap biotech companies across multiple therapeutic areas with a specialization in neuroscience. Rudy earned a Ph.D. in Chemistry from Stony Brook University, and a B.S. in Chemistry from Jilin University.